Everything below concerns growth hormone secretagogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Selenoprotein I (SELENOI/EPT1), a CDP-ethanolamine:diacylglycerol ethanolamine-phosphotransferase. Selenoprotein K and Selenoprotein S are small transmembrane proteins found on the ER menbrane. Selenoprotein M and Selenoprotein F, thioredoxin-like proteins found in the endoplasmic reticulum (ER). Selenoprotein N, a large transmembran proteins found on the ER menbrane. Selenoprotein O, protein found in the mitochondrial, probably with a redox function. Selenoprotein P is an extracellular glycoprotein, unusually with more than one Sec residue (usually several), found in eukaryotes including humans. The precise number of residues vary and appears linked to the selenium needs of the organism. Selenoprotein R (MSRB1) is a peptide-methionine (R)-S-oxide reductase. It has two non-selenoprotein relatives in humans, also of the same catalytic activity. Families only existing as non-seleno-proteins in mammals:
Less is understood about atypical (non-lysine 48-linked) ubiquitin chains but research is starting to suggest roles for these chains. There is evidence that atypical chains linked by lysine 6, 11, 27, 29 and methionine 1 can induce proteasomal degradation. Branched ubiquitin chains containing multiple linkage types can be formed. The function of these chains is unknown.
== Antiangiogenic antithrombin == Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. Under normal physiological conditions angiogenesis is tightly regulated and is controlled by a balance of angiogenic stimulators and angiogenic inhibitors. Tumor growth is dependent upon angiogenesis and during tumor development a sustained production of angiogenic stimulatory factors is required along with a reduction in the quantity of angiogenic inhibitory factors tumor cells produce. The cleaved and latent form of antithrombin potently inhibit angiogenesis and tumor growth in animal models. The prelatent form of antithrombin has been shown to inhibit angiogenesis in-vitro but to date has not been tested in experimental animal models.
=== Epitope mapping === Due to their various epitopes, antibodies have gained interest in both basic and clinical research. The foundation of antibody characterization and validation is epitope mapping. The procedure of identifying an antibody's binding sites (epitopes) on the target protein is referred to as "epitope mapping." Finding the binding epitope of an antibody is essential for the discovery and creation of novel vaccines, diagnostics, and therapeutics. As a result, various methods for mapping antibody epitopes have been created. At this point, Western blotting's specificity is the main feature that sets it apart from other epitope mapping techniques. There are several application of Western blot for epitope mapping on human skin samples, hemorrhagic disease virus.
Carbohydrates, including interactive models and animations (Requires MDL Chime) IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (JCBN): Carbohydrate Nomenclature Carbohydrates detailed Carbohydrates and Glycosylation – The Virtual Library of Biochemistry, Molecular Biology and Cell Biology Functional Glycomics Gateway, a collaboration between the Consortium for Functional Glycomics and Nature Publishing Group
Sources: en.wikipedia.org
Esterification of L-glutamic acid [56-86-0] (1) with ethanol gives Glutamic acid diethyl ester [16450-41-2] (2). Lactam formation occurs on heating to give L-Pyroglutamic acid ethyl ester [7149-65-7] (3). The reduction of the ester with sodium borohydride gives L-Pyroglutaminol [17342-08-4] (4). Treatment with methyl chloride gave (S)-(5-Oxopyrrolidin-2-yl)methyl methanesulfonate [93288-20-1] (5). Displacement of the leaving group with cyanide led to (S)-5-Oxo-2-pyrrolidineacetonitrile [72479-06-2] (6). Catalytic reduction over Rosenmund catalyst in the presence of dimethylamine led to (5S)-5-[2-(dimethylamino)ethyl]pyrrolidin-2-one, PC13306712 (7). Oxidation in the presence of hydrogen peroxide formed the N-oxide (8). Elimination of the amino group in the presence of weak base led to (S)-5-Vinylpyrrolidin-2-one [93288-23-4] (9). Alkylation of the amino group with 2-Chlorobenzyl chloride [611-19-8] (10) in the presence of sodium hydride base led to (5S)-1-[(2-chlorophenyl)methyl]-5-ethenylpyrrolidin-2-one, PC56976994 (11). Treatment of the vinyl group with peroxy acid gave the oxirane. (5S)-1-[(2-chlorophenyl)methyl]-5-(oxiran-2-yl)pyrrolidin-2-one, PC88496451 (12). Treatment with (2R)-N-[(2R)-butan-2-yl]butan-2-amine, PC6347588 (13) completed the synthesis of Z4349 (14).
The history of the mole is intertwined with that of units of molecular mass, and the Avogadro constant. The first table of standard atomic weight was published by John Dalton (1766–1844) in 1805, based on a system in which the relative atomic mass of hydrogen was defined as 1. These relative atomic masses were based on the stoichiometric proportions of chemical reaction and compounds, a fact that greatly aided their acceptance; it was not necessary for a chemist to subscribe to atomic theory (which was not universally accepted at the time) to make practical use of the tables. This would lead to some confusion between atomic masses (promoted by proponents of atomic theory) and equivalent weights (promoted by its opponents and which sometimes differed from relative atomic masses by an integer factor), which would last throughout much of the nineteenth century. Jöns Jacob Berzelius (1779–1848) was instrumental in the determination of relative atomic masses to ever-increasing accuracy. He was also the first chemist to use oxygen as the standard to which other masses were referred. Oxygen is a useful standard, as, unlike hydrogen, it forms compounds with most other elements, especially metals. However, he chose to fix the atomic mass of oxygen as 100, which did not catch on. Charles Frédéric Gerhardt (1816–56), Henri Victor Regnault (1810–78) and Stanislao Cannizzaro (1826–1910) expanded on Berzelius' works, resolving many of the problems of unknown stoichiometry of compounds, and the use of atomic masses attracted a large consensus by the time of the Karlsruhe Congress (1860).
Ethylestrenol, also known as ethyloestrenol or ethylnandrol and sold under the brand names Maxibolin and Orabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used in the past for a variety of indications such as to promote weight gain and to treat anemia and osteoporosis but has been discontinued for use in humans. It is still available for veterinary use in Australia and New Zealand however. It is taken by mouth. Side effects of ethylestrenol include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. It can also cause liver damage. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong anabolic effects relative to its androgenic effects. The drug also has strong progestogenic effects. Ethylestrenol is a prodrug of norethandrolone. Ethylestrenol was first described in 1959 and was introduced for medical use in 1961. In addition to its medical use, ethylestrenol has been used to improve physique and performance. However, it is described as a very weak muscle-builder compared to other AAS and in relation to this has not been commonly used for such purposes. The drug is a controlled substance in many countries and so non-medical use is generally illicit.
Thomas A. Wadden (born September 3, 1952) is an American psychologist who is known for his research on the behavioral, pharmacological, and surgical treatment of obesity. He is Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, where he served as Director of the Center for Weight and Eating Disorders for over two decades. From 2011 to 2021, he held the endowed Albert J. Stunkard Professorship in Psychiatry. Wadden has published more than 500 peer-reviewed scientific papers and edited seven volumes on obesity and eating disorders. He has contributed to national health policy on obesity management, serving on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the United States House of Representatives. He is a fellow of The Obesity Society. In 2015, The Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.
== L == Lamina A layer of neurons in a neural structure. In the spinal cord and cerebral cortex, laminae are functionally and anatomically distinct. Lateral geniculate nucleus (LGN) A relay center in the thalamus that receives input from the retina and sends visual information to the visual cortex. Lateral inhibition A neural mechanism in which an excited neuron reduces the activity of its neighbors. Enhances contrast in sensory systems such as vision and touch. Lateral sulcus A deep groove in the cerebral cortex that separates the frontal lobe and parietal lobe from the temporal lobe. Learning The acquisition of new knowledge or skills through experience, study, or teaching. In neuroscience, learning is linked to synaptic plasticity and neural circuit changes. Learning A neurobiological process through which experience induces lasting changes in the nervous system, leading to the acquisition or modification of behavior, knowledge, or skills. Lentiform nucleus A structure within the basal ganglia composed of the putamen and globus pallidus, involved in motor control and learning. Lesion Damage or abnormal change in brain tissue, caused by injury, stroke, disease, or surgery. Lesion studies are used to investigate brain function. Levodopa A precursor to dopamine used in the treatment of Parkinson’s disease. It crosses the blood–brain barrier and is converted to dopamine in the brain. Limbic system A group of interconnected brain structures involved in emotion, motivation, memory, and olfaction. Includes the amygdala, hippocampus, and cingulate cortex.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.